137 related articles for article (PubMed ID: 38710984)
1. Correction to: Magnetic Resonance Spectroscopy (MRS) in Alzheimer's Disease.
Sheikh-Bahaei N; Chen M; Pappas I
Methods Mol Biol; 2024; 2785():C1. PubMed ID: 38710984
[No Abstract] [Full Text] [Related]
2. Magnetic resonance imaging and magnetic resonance spectroscopy for detection of early Alzheimer's disease.
Westman E; Wahlund LO; Foy C; Poppe M; Cooper A; Murphy D; Spenger C; Lovestone S; Simmons A
J Alzheimers Dis; 2011; 26 Suppl 3():307-19. PubMed ID: 21971470
[TBL] [Abstract][Full Text] [Related]
3. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
Modrego PJ; Pina MA; Fayed N; Díaz M
CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
[TBL] [Abstract][Full Text] [Related]
4. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
[TBL] [Abstract][Full Text] [Related]
5. Magnetic Resonance Spectroscopy (MRS) in Alzheimer's Disease.
Sheikh-Bahaei N; Chen M; Pappas I
Methods Mol Biol; 2024; 2785():115-142. PubMed ID: 38427192
[TBL] [Abstract][Full Text] [Related]
6. Utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy as adjunct techniques for screening and predicting dementia due to Alzheimer's disease in clinical practice.
Waragai M; Hata S; Suzuki T; Ishii R; Fujii C; Tokuda T; Arai H; Ohrui T; Higuchi S; Yoshida M; Igarashi K; Moriya M; Iwai N; Uemura K
J Alzheimers Dis; 2014; 41(4):1207-22. PubMed ID: 24787913
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance spectroscopy in Alzheimer's disease.
Graff-Radford J; Kantarci K
Neuropsychiatr Dis Treat; 2013; 9():687-96. PubMed ID: 23696705
[TBL] [Abstract][Full Text] [Related]
8. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist.
Satlin A; Bodick N; Offen WW; Renshaw PF
Am J Psychiatry; 1997 Oct; 154(10):1459-61. PubMed ID: 9326834
[TBL] [Abstract][Full Text] [Related]
9. Treatment effects in a transgenic mouse model of Alzheimer's disease: a magnetic resonance spectroscopy study after passive immunization.
Marjańska M; Weigand SD; Preboske G; Wengenack TM; Chamberlain R; Curran GL; Poduslo JF; Garwood M; Kobayashi D; Lin JC; Jack CR
Neuroscience; 2014 Feb; 259():94-100. PubMed ID: 24316473
[TBL] [Abstract][Full Text] [Related]
10. Estimating the synaptic density deficit in Alzheimer's disease using multi-contrast CEST imaging.
Shahid SS; Dzemidzic M; Butch ER; Jarvis EE; Snyder SE; Wu YC
PLoS One; 2024; 19(3):e0299961. PubMed ID: 38483851
[TBL] [Abstract][Full Text] [Related]
11. The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial.
Rijpma A; van der Graaf M; Lansbergen MM; Meulenbroek O; Cetinyurek-Yavuz A; Sijben JW; Heerschap A; Olde Rikkert MGM
Alzheimers Res Ther; 2017 Jul; 9(1):51. PubMed ID: 28747210
[TBL] [Abstract][Full Text] [Related]
12. Neurodegenerative Changes in the Brains of the 5xFAD Alzheimer's Disease Model Mice Investigated by High-Field and High-Resolution Magnetic Resonance Imaging and Multi-Nuclei Magnetic Resonance Spectroscopy.
Yoo CH; Kim J; Baek HM; Chang KA; Choe BY
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982146
[TBL] [Abstract][Full Text] [Related]
13. Combining MRI and MRS to distinguish between Alzheimer's disease and healthy controls.
Westman E; Wahlund LO; Foy C; Poppe M; Cooper A; Murphy D; Spenger C; Lovestone S; Simmons A
J Alzheimers Dis; 2010; 22(1):171-81. PubMed ID: 20847449
[TBL] [Abstract][Full Text] [Related]
14. The partial volume effect in the quantification of 1H magnetic resonance spectroscopy in Alzheimer's disease and aging.
Mato Abad V; Quirós A; García-Álvarez R; Loureiro JP; Alvarez-Linera J; Frank A; Hernández-Tamames JA
J Alzheimers Dis; 2014; 42(3):801-11. PubMed ID: 24927708
[TBL] [Abstract][Full Text] [Related]
15. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Pina MA
Am J Psychiatry; 2005 Apr; 162(4):667-75. PubMed ID: 15800137
[TBL] [Abstract][Full Text] [Related]
16. An 1H-MRS framework predicts the onset of Alzheimer's disease symptoms in PSEN1 mutation carriers.
Londono AC; Castellanos FX; Arbelaez A; Ruiz A; Aguirre-Acevedo DC; Richardson AM; Easteal S; Lidbury BA; Arcos-Burgos M; Lopera F
Alzheimers Dement; 2014 Sep; 10(5):552-61. PubMed ID: 24239247
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
García Santos JM; Gavrila D; Antúnez C; Tormo MJ; Salmerón D; Carles R; Jiménez Veiga J; Parrilla G; Torres del Río S; Fortuna L; Navarro C
Dement Geriatr Cogn Disord; 2008; 26(1):15-25. PubMed ID: 18566544
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease.
Dixon RM; Bradley KM; Budge MM; Styles P; Smith AD
Brain; 2002 Oct; 125(Pt 10):2332-41. PubMed ID: 12244089
[TBL] [Abstract][Full Text] [Related]
19. Nuclear magnetic resonance spectroscopy: a review of neuropsychiatric applications.
Passe TJ; Charles HC; Rajagopalan P; Krishnan KR
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jul; 19(4):541-63. PubMed ID: 8588055
[TBL] [Abstract][Full Text] [Related]
20. Multifaceted assessment of the APP/PS1 mouse model for Alzheimer's disease: Applying MRS, DTI, and ASL.
Shen Z; Lei J; Li X; Wang Z; Bao X; Wang R
Brain Res; 2018 Nov; 1698():114-120. PubMed ID: 30077647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
